AstraZeneca PLC (AZN) Financials
PeriodQ2 FY2026
Published
AstraZeneca reported total revenue of $15.38 billion for Q2 FY2026, the quarter ended June 30, 2026, up 6.4% from a year earlier, and net income attributable to shareholders of $2.51 billion, up 2.3%, or $1.61 per diluted ordinary share. Operating profit was $3.16 billion, down 9.8%, because of larger charges that AstraZeneca excludes from its Core measures, mainly intangible amortisation and impairments, including write-downs of development-stage intangible assets in research and development, but a lower tax charge more than offset that decline at the net income line. On its Core basis, which also excludes restructuring costs and other listed items, costs grew roughly in line with revenue, Core operating profit rose and AstraZeneca earned $2.63 per share.
| Metric | Amount | vs. year ago |
|---|---|---|
| Revenue | $15,384,000,000 | up 6.4% |
| Net income | $2,507,000,000 | up 2.3% |
| Diluted EPS | $1.61 | up 2.5% |
| Operating profit | $3,164,000,000 | down 9.8% |
| Core EPS | $2.63 |
Company details
| Name | Astrazeneca Plc |
|---|---|
| Ticker | AZN |
| CIK | 0000901832 |
| Exchange | NYSE |
| Incorporation | United Kingdom |
| SIC | 2834 |
| Office | Life Sciences |
| Industry | Pharmaceutical Preparations |
| Latest period covered | Q2 FY2026, ended 2026-06-30, 6-K, accession 0001104659-26-086846 |
| Fiscal year end | 12/31 (MM/DD) |
| Next expected filing | 6-K around 2026-11-05 (predicted) |
Data files
- Financial statementsPage Annual financial statements plus the latest quarter: income statement, balance sheet, cash flow. Actual dollars, actual shares. Sourcing notes and uncertainties included, plus a figure_sources block linking each figure the filing tags to the line that prints it.
- 20-F and 6-K summaryPage Qualitative synthesis of the latest 20-F + 6-K: business, risk factors (quarter-over-quarter changes flagged), MD&A, legal proceedings, subsequent events.
- 6-K filings and eventsPage Digest of material 6-K filings: earnings headlines, management changes, capital-return and financing actions, governance. SEC accession numbers cited throughout.
FAQ · AstraZeneca Q2 FY2026
How much revenue did AstraZeneca make in Q2 FY2026?
AstraZeneca reported total revenue of $15.38 billion for Q2 FY2026, the quarter ended June 30, 2026. That is up 6.4% from $14.46 billion in the same quarter a year earlier.
What were AstraZeneca's net income and EPS in Q2 FY2026?
AstraZeneca's net income attributable to shareholders was $2.51 billion in Q2 FY2026, up 2.3% from $2.45 billion a year earlier. Diluted earnings per ordinary share were $1.61, against $1.57 in the same quarter a year earlier.
Why did AstraZeneca's operating profit fall in Q2 FY2026?
AstraZeneca's operating profit was $3.16 billion in Q2 FY2026, down 9.8% from $3.51 billion a year earlier, because of larger charges that AstraZeneca excludes from its Core measures: impairments of development-stage intangible assets in research and development, and intangible amortisation and impairments, restructuring and other listed items in selling, general and administrative costs. On its Core basis, costs grew roughly in line with revenue and Core operating profit rose. Despite the lower reported operating profit, a lower tax charge, which reflected an adjustment to deferred tax assets, meant AstraZeneca's net income still rose to $2.51 billion.
What was AstraZeneca's Core EPS in Q2 FY2026?
AstraZeneca reported Core earnings per share of $2.63 for Q2 FY2026, the quarter ended June 30, 2026. Core EPS is the company's own measure, not an IFRS figure; it excludes intangible amortisation and impairments, restructuring costs and other items the company lists, and compares with reported diluted EPS of $1.61.
Where can I get AstraZeneca PLC (AZN) financial data in machine-readable form?
Ticker Scout publishes AstraZeneca PLC's financial statements as JSON at https://tickerscout.ai/azn/financials.json, free, with no API key and no signup. The 20-F and 6-K narrative and the 6-K events digest are published as Markdown at https://tickerscout.ai/azn/narrative.md and https://tickerscout.ai/azn/events.md. AstraZeneca PLC's SEC CIK is 0000901832. Every figure cites the SEC accession number it came from, so it can be checked against sec.gov.
When does AstraZeneca PLC (AZN) next file with the SEC?
AstraZeneca PLC (AZN) is expected to file its next Form 6-K with the SEC on or around November 5, 2026. That date is a projection rather than a company-announced date: it is derived from AstraZeneca PLC's own filing history with the SEC, by taking the date the company filed the same fiscal period a year earlier and adding 52 weeks. The most recent periodic report on file is the 6-K for Q2 FY2026, the period ended 2026-06-30, SEC accession 0001104659-26-086846.
Related companies
How this page was built
This page was built from AstraZeneca PLC's own filings with the SEC, read one at a time, and nothing on it is taken from a pre-tagged dataset, a data vendor or another website. The figures are on the company's own fiscal calendar and in actual dollars, as the filings report them. Where the filings do not support a figure, the record says so instead of reporting a zero; this period names two such gaps.
A single company files thousands of pages with the SEC in a year, and no two companies file them the same way, so the reading and the assembly here are done by AI rather than by rules that break on the differences. Every pass is then audited back against the filings it came from before the page is published, and anything the filings do not support is left out and named rather than filled in. AI can still make mistakes. That is why the accession numbers are printed: the filing is the authority, and this page is a route to it.
Published by Ticker Scout, an independent publisher of company filings data. About Ticker Scout · Disclaimer
Data extracted from SEC filings (accession numbers cited in each file). The undated URLs hold the latest period and are replaced in place each quarter; every period also stays published at its own dated URL, which never changes. Free to cite with attribution: Ticker Scout (tickerscout.ai). Not investment advice, see the Disclaimer.